UNLABELLED: Diffuse large B-cell lymphoma (DLCL) accounts for 30-40% of adult non-Hodgkin's Lymphoma (NHL). Current anti-NHL therapies often target cellular growth suppression pathways and include R-CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone plus monoclonal anti-CD20 antibody rituximab). However, since many patients relapse, resistant cells to these therapies remain a significant problem and necessitate development of new intervention strategies. Cell cycle and apoptosis regulatory protein (CARP)-1 functions in a biphasic manner to regulate growth factor as well as chemotherapy (adriamycin, etoposide, or iressa)-dependent signaling. PURPOSE: To determine whether CARP-1 is a novel suppressor of lymphoma growth. METHODS: Flow cytometric analyses coupled with Western immunoblotting, cell growth, apoptosis, and immunocytochemistry methodologies were utilized to determine CARP-1-dependent lymphoma growth inhibition in vitro and in vivo. RESULTS: CARP-1 expression correlated with activated caspase-3 and inversely correlated with activated Akt in DLCL. Exposure to adriamycin stimulated CARP-1 expression and inhibited growth of Raji cells, but not CHOP-resistant WSU-DLCL2 cells. Expression of wild-type CARP-1 or its apoptosis-inducing mutants inhibited growth of Raji as well as CHOP-resistant WSU-DLCL2 cells, in part by activating caspase-9 and apoptosis. Since CARP-1 harbors multiple, apoptosis-promoting subdomains, we investigated whether epigenetic compensation of CARP-1 function by intracellular delivery of trans-activator of transcription (TAT) domain-tagged CARP-1 peptide(s) will inhibit lymphoma growth. Treatments with TAT-tagged CARP-1 peptides suppressed growth of the Raji and WSU-DLCL2 cells by stimulating apoptosis. TAT-CARP-1 (1-198) as well as (896-1150) peptides also suppressed growth of WSU-DLCL2 cell-derived tumor xenografts in SCID mice, while administration of TAT-CARP-1 (1-198) also inhibited growth of WSU-FSCCL cell-derived ascites and prolonged host survival. CONCLUSION: CARP-1 is a suppressor of NHL growth and could be exploited for targeting the resistant DLCL.
UNLABELLED: Diffuse large B-cell lymphoma (DLCL) accounts for 30-40% of adult non-Hodgkin's Lymphoma (NHL). Current anti-NHL therapies often target cellular growth suppression pathways and include R-CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone plus monoclonal anti-CD20 antibody rituximab). However, since many patients relapse, resistant cells to these therapies remain a significant problem and necessitate development of new intervention strategies. Cell cycle and apoptosis regulatory protein (CARP)-1 functions in a biphasic manner to regulate growth factor as well as chemotherapy (adriamycin, etoposide, or iressa)-dependent signaling. PURPOSE: To determine whether CARP-1 is a novel suppressor of lymphoma growth. METHODS: Flow cytometric analyses coupled with Western immunoblotting, cell growth, apoptosis, and immunocytochemistry methodologies were utilized to determine CARP-1-dependent lymphoma growth inhibition in vitro and in vivo. RESULTS:CARP-1 expression correlated with activated caspase-3 and inversely correlated with activated Akt in DLCL. Exposure to adriamycin stimulated CARP-1 expression and inhibited growth of Raji cells, but not CHOP-resistant WSU-DLCL2 cells. Expression of wild-type CARP-1 or its apoptosis-inducing mutants inhibited growth of Raji as well as CHOP-resistant WSU-DLCL2 cells, in part by activating caspase-9 and apoptosis. Since CARP-1 harbors multiple, apoptosis-promoting subdomains, we investigated whether epigenetic compensation of CARP-1 function by intracellular delivery of trans-activator of transcription (TAT) domain-tagged CARP-1 peptide(s) will inhibit lymphoma growth. Treatments with TAT-tagged CARP-1peptides suppressed growth of the Raji and WSU-DLCL2 cells by stimulating apoptosis. TAT-CARP-1 (1-198) as well as (896-1150) peptides also suppressed growth of WSU-DLCL2 cell-derived tumor xenografts in SCIDmice, while administration of TAT-CARP-1 (1-198) also inhibited growth of WSU-FSCCL cell-derived ascites and prolonged host survival. CONCLUSION:CARP-1 is a suppressor of NHL growth and could be exploited for targeting the resistant DLCL.
Authors: M A Shipp; M D Abeloff; K H Antman; G Carroll; A Hagenbeek; M Loeffler; E Montserrat; J A Radford; G Salles; N Schmitz; M Symann; J O Armitage; T Philip; B Coiffier Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: Sean A Beausoleil; Mark Jedrychowski; Daniel Schwartz; Joshua E Elias; Judit Villén; Jiaxu Li; Martin A Cohn; Lewis C Cantley; Steven P Gygi Journal: Proc Natl Acad Sci U S A Date: 2004-08-09 Impact factor: 11.205
Authors: Magesh Muthu; Jaganmohan Somagoni; Vino T Cheriyan; Sara Munie; Edi Levi; Abdelkader E Ashour; Alaa Eldeen B Yassin; Ahmed M Alafeefy; Paula Sochacki; Lisa A Polin; Kaladhar B Reddy; Scott D Larsen; Mandip Singh; Arun K Rishi Journal: J Biomed Nanotechnol Date: 2015-09 Impact factor: 4.099
Authors: Vineshkumar Thidil Puliyappadamba; Wenjuan Wu; Debra Bevis; Liyue Zhang; Lisa Polin; Robert Kilkuskie; Russell L Finley; Scott D Larsen; Edi Levi; Fred R Miller; Anil Wali; Arun K Rishi Journal: J Biol Chem Date: 2011-09-08 Impact factor: 5.157